Login to Your Account


Three's company? TNBC heats up as Medivation, others crowd the space

By Randy Osborne
Staff Writer

Thursday, June 4, 2015

Complete with an assay that helps select eligible patients, the approved prostate-cancer (PC) drug Xtandi (enzalutamide) from Medivation Inc. and partner Astellas Pharma Inc. turned up hopeful phase II results in androgen-receptor (AR)-positive triple-negative breast cancer (TNBC), detailed at the recently concluded meeting of the American Society of Clinical Oncology in Chicago.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription